Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
115.52
+0.89 (0.78%)
At close: Aug 1, 2025, 4:00 PM
110.00
-5.52 (-4.78%)
After-hours: Aug 1, 2025, 6:27 PM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Jazz Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $183, which forecasts a 58.41% increase in the stock price over the next year. The lowest target is $147 and the highest is $230.
Price Target: $183.00 (+58.41%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 5 | 5 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Hold | 3 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 13 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $166 → $165 | Buy | Maintains | $166 → $165 | +42.83% | Jul 22, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +74.86% | Jun 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +74.86% | Jun 3, 2025 |
| Baird | Baird | Buy Maintains $167 → $155 | Buy | Maintains | $167 → $155 | +34.18% | May 7, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $182 → $172 | Buy | Maintains | $182 → $172 | +48.89% | May 7, 2025 |
Financial Forecast
Revenue This Year
4.32B
from 4.07B
Increased by 6.10%
Revenue Next Year
4.54B
from 4.32B
Increased by 5.07%
EPS This Year
4.86
from 8.65
Decreased by -43.83%
EPS Next Year
22.02
from 4.86
Increased by 353.19%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.6B | 5.1B | 5.6B | ||
| Avg | 4.3B | 4.5B | 4.8B | ||
| Low | 4.0B | 3.9B | 4.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.5% | 18.9% | 23.6% | ||
| Avg | 6.1% | 5.1% | 6.8% | ||
| Low | -2.0% | -8.6% | -8.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.78 | 26.34 | 29.41 | ||
| Avg | 4.86 | 22.02 | 23.80 | ||
| Low | 3.03 | 15.76 | 10.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -33.2% | 442.3% | 33.6% | ||
| Avg | -43.8% | 353.2% | 8.1% | ||
| Low | -65.0% | 224.4% | -51.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.